First-In-Man Dose Escalation Study of Aspirin® Inhaled For The Clinical Development of A New Antiviral Treatment of Resistant Influenza

TOTAL INDEX Mynocicline (N = 21) 14 (66.7%) 3.4 1.9 (−4 – 11) Placebo (N = 11) 7 (63.7%) 3.7 2.0 (−1 – 9) Cognitive Mynocicline (N = 21) 13 (61.9) 2.8 1.5 (−2 – 6) Placebo (N = 11) 8 (72.7%) 5.4 3.5 (−2 – 13) Gross Motor Mynocicline (N = 21) 14 (66.7%) 2.9 1.2 (−8 – 5) Placebo (N = 11) 5 (45.5%) 4.6 0 (−16 – 15) Fine Motor Mynocicline (N = 21) 11 (52.4%) 4.5 2.0 (−3 – 13) Placebo (N = 11) 8 (72.7%) 4.4. 2.6 (−3 – 10) Total Index language Mynocicline (N = 21) 0 Placebo (N = 11) 0 Processing speed Mynocicline (N = 21) 0 Placebo (N = 11) 0 Adaptive behaviour/daily life skills Mynocicline (N = 21) 10 (47.6%) 3.2 0.9 (−4 – 11) Placebo (N = 11) 5 (45.5%) 4.2 1.0 (−5 – 13)